Resistance-Associated Variants in HCV Subtypes 1a and 1b Detected by Ion Torrent Sequencing Platform

Abstract

Background

As a result of increased understanding of the HCV life cycle, a new generation of drugs known as direct-acting antivirals (DAAs) was developed and is constantly being improved. At baseline, HCV variants resistant to DAA therapy may pre-exist, increasing the likelihood of treatment failure. The aim of this study was to investigate the presence of resistance-associated variants (RAVs) in treatment-naive patients infected with HCV subtypes 1a and 1b.

Methods

Next-generation sequencing was used to assess the frequencies of NS3-4A, NS5A and NS5B RAVs in 100 HCV monoinfected DAA-naive patients (HCV-1a: n=51; HCV-1b: n=49).

Results

Complete HCV sequence information was obtained for most samples. RAVs were detected in the NS3-4A (T54S, V55A, Q80K and R155K), NS5A (Q30H/R, H58P and Y93C/H/N) and NS5B (A421V) regions in 10%, 22% and 8%, respectively, of patients infected with HCV subtype-1a. Among the patients infected with HCV subtype-1b, mutations in the NS3-4A (F43I, T54S, Q80H, D168E and M175L), NS5A (L28M, R30Q, L31M, Q54H, A92T and Y93H) and NS5B (L159F, C316N, A421V and S556G) regions were observed in 12%, 53% and 31% of patients, respectively.

Conclusions

High-throughput DNA sequencing allows an easier and more complete analysis of DAA RAVs, including mutations that represent only a minor variant of the whole viral population. RAVs to the three different classes of DAAs were found in our population. The characterization of their profile in the circulating virus is relevant to determine the better treatment option for infected individuals or to guide the implementation of treatment policies.

References

Roelandt

, Obeid

, Paeshuyse

Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus.

J Hepatol 2012; 57: 246–251.

, Wu

N.C.

, Du

, Wu

T.T.

, Sun

High-resolution genetic profile of viral genomes: why it matters.

Curr Opin Virol 2015; 14: 62–70.

US Food and Drug Administration. FDA news release. FDA approves Victrelis for hepatitis C. (Updated 23 May 2011. Accessed 2 December 2015.) Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm.

US Food and Drug Administration. FDA news release. FDA approves Incivek for hepatitis C. (Updated 23 May 2011. Accessed 2 December 2015.) Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm.

Flamm

S.L.

, Lawitz

, Jacobson

Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.

Clin Gastroenterol Hepatol 2013; 11: 81–87.e84.

Kieffer

T.L.

, De Meyer

, Bartels

D.J.

Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

PLoS ONE 2012; 7: e34372.

European Association for Study of Liver.

EASL recommendations on treatment of hepatitis C 2015.

J Hepatol 2015; 63: 199–236.

Perry

C.M.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Drugs 2012; 72: 619–641.

Poordad

, McCone

Jr. , Bacon

B.R.

Boceprevir for untreated chronic HCV genotype 1 infection.

N Engl J Med 2011; 364: 1195–1206.

10.

Vermehren

, Sarrazin

New HCV therapies on the horizon.

Clin Microbiol Infect 2011; 17: 122–134.

11.

Foster

G.R.

, Afdhal

, Roberts

S.K.

Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.

N Engl J Med 2015; 373: 2608–2617.

12.

Cuypers

, Li

, Libin

, Piampongsant

, Vandamme

A.M.

, Theys

Genetic diversity and selective pressure in hepatitis C virus genotypes 1–6: significance for direct-acting antiviral treatment and drug resistance.

Viruses 2015; 7: 5018–5039.

13.

Feld

J.J.

, Jacobson

I.M.

, Hezode

Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.

N Engl J Med 2015; 373: 2599–2607.

14.

Gane

E.J.

, Roberts

S.K.

, Stedman

C.A.

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.

Lancet 2010; 376: 1467–1475.

15.

Zeuzem

, Buggisch

, Agarwal

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Hepatology 2012; 55: 749–758.

16.

Vandamme

A.M.

, Camacho

R.J.

, Ceccherini Silberstein

European recommendations for the clinical use of HIV drug resistance testing: 2011 update.

AIDS Rev 2011; 13: 77–108.

17.

Pawlotsky

J.M.

New hepatitis C therapies: the toolbox, strategies, and challenges.

Gastroenterology 2014; 146: 1176–1192.

18.

Sarrazin

The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

J Hepatol 2016; 64: 486–504.

19.

Garson

J.A.

, Ring

, Tuke

, Tedder

R.S.

Enhanced detection by PCR of hepatitis C virus RNA.

Lancet 1990; 336: 878–879.

20.

Rothberg

J.M.

, Hinz

, Rearick

T.M.

An integrated semiconductor device enabling non-optical genome sequencing.

Nature 2011; 475: 348–352.

21.

Loman

N.J.

, Misra

R.V.

, Dallman

T.J.

Performance comparison of benchtop high-throughput sequencing platforms.

Nat Biotechnol 2012; 30: 434–439.

22.

Applegate

T.L.

, Gaudieri

, Plauzolles

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

Antivir Ther 2015; 20: 199–208.

23.

Lenz

, Fevery

, Verbinnen

Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies.

Hepatology 2013; 58: 793A.

24.

Jacobson

, Dore

G.J.

, Foster

G.R.

Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a Phase III trial.

J Hepatol 2013; 58 Suppl 1: S574.

25.

Lisboa-Neto

, Noble

C.F.

, Pinho

J.R.

Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection.

Antivir Ther 2014; 20: 281–287.

26.

Sølund

, Krarup

, Ramirez

Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.

PLoS ONE 2014; 9: e113034.

27.

Hoffmann

, Faffe

D.S.

, Lima

J.F.

No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy.

BBA Clin 2015; 3: 146–151.

28.

Uchida

, Kouyama

J.I.

, Naiki

Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.

J Gastroenterol 2016; 51: 260–270.

29.

Yoshimi

, Imamura

, Murakami

Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.

J Med Virol 2015; 87: 1913–1920.

30.

U.S. Food and Drug Administration news release. FDA approves Zepatier for hepatitis C. (Accessed 25 February 2016.) Available from http://www:accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.

31.

Forns

, Gordon

S.C.

, Zuckerman

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.

J Hepatol 2015; 63: 564–572.

32.

Pawlotsky

J.M.

Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens.

Gastroenterology 2016; 151: 70–86.

33.

Paolucci

, Fiorina

, Mariani

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients.

Virol J 2013; 10: 355.

34.

Donaldson

E.F.

, Harrington

P.R.

, O'Rear

J.J.

, Naeger

L.K.

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.

Hepatology 2015; 61: 56–65.

35.

Pol

, Sulkowski

M.S.

, Hassanein

Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.

Hepatology 2015; 62: 129–134.

36.

Chulanov

, Zhdanov

, Kersey

Sofosbuvir plus ribavirin for the treatment of Russian patients with chronic HCV genotype 1 or 3 infection. 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD). Boston, MA, USA. 7–11 November 2014. Abstract 982.

37.

Margeridon-Thermet

, Le Pogam

, Li

Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing.

PLoS ONE 2014; 9: e105569.

38.

Aissa Larousse

, Trimoulet

, Recordon-Pinson

Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.

J Med Virol 2014; 86: 1350–1359.

39.

Di Maio

V.C.

, Cento

, Mirabelli

Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.

Antimicrob Agents Chemother 2014; 58: 2781–2797.

40.

Ribeiro

R.M.

, Li

, Wang

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate.

PLoS Pathog 2012; 8: e1002881.

41.

Fourati

, Pawlotsky

J.M.

Virologic tools for HCV drug resistance testing.

Viruses 2015; 7: 6346–6359.

42.

Capobianchi

M.R.

, Giombini

, Rozera

Next-generation sequencing technology in clinical virology.

Clin Microbiol Infect 2013; 19: 15–22.

43.

Bartels

D.J.

, Sullivan

J.C.

, Zhang

E.Z.

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

J Virol 2013; 87: 1544–1553.

44.

Dietz

, Susser

, Berkowski

, Perner

, Zeuzem

, Sarrazin

Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients.

PLoS ONE 2015; 10: e0134395.

45.

Sarrazin

, Lathouwers

, Peeters

Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.

Antiviral Res 2015; 116: 10–16.

46.

Fridell

R.A.

, Wang

, Sun

J.H.

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

Hepatology 2011; 54: 1924–1935.

47.

Sarrazin

, Dvory-Sobol

, Svarovskaia

E.S.

, Doehle

, McCarville

J.F.

, Pang

P.S.

Baseline and post-baseline resistance analyses of Phase 2/3 studies of ledipasvir/sofosbuvir +/- RBV.

Hepatology 2014; 60: 1128a.